FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221130267> ?p ?o ?g. }

• W4221130267 endingPage "930" @default.
• W4221130267 startingPage "923" @default.
• W4221130267 abstract "Secondary graft failure (SGF) is a fatal complication of allogeneic hematopoietic stem cell transplantation without effective treatment methods, especially after haploidentical transplantation. This study aimed to analyze the efficacy of donor lymphocyte infusion (DLI) from a second donor in treating SGF and the underlying immune mechanisms. A second donor is a candidate donor who did not initially provide stem cells for HLA-matched sibling donor or HLA-haploidentical donor transplantation. We conducted a retrospective study of 237 patients with a median age of 38 years (range 9-56) for whom the degree of mixed chimerism (MC) and complete donor chimerism (CC), mRNA expression levels of Forkhead box P3 (Foxp3), and the proportion of regulatory T cells (Tregs) were regularly assessed. The median time to SGF was 62 days (range 41-117) after transplantation. Twenty-one patients with SGF received DLI, including 12 patients who initially received DLI from a second donor (i.e., a donor other than the transplantation [first] donor) and 9 patients who initially received DLI from the first donor but showed no response. Three of those 9 patients subsequently received DLI from a second donor. The incidence of acute GVHD and chronic GVHD induced by DLI from the second donor was significantly higher than that of DLI from the first donor (P = 0.006). Twenty-one patients with SGF exhibited synchronous MC, and the overall MC rate after transplantation was 65% (range 42%-85%).The proportion of Tregs significantly decreased in SGF patients, from a median of 2.61% ± 0.88% to 0.92% ± 0.23% at the indicated time point after transplantation (P = 0.03). Second-donor DLI resulted in a complete response (CR) in 13 patients, and MC gradually converted into CC; simultaneously, there was a significant increase in the mRNA level of Foxp3 and the proportion of Tregs (baseline, 0.92% ± 0.23% versus CR, 3.61% ± 0.82%; P = 0.01). For the patients who did not respond to DLI from either donor type, there was no significant change in donor chimerism, Foxp3 expression level or Treg proportion. Overall survival and disease-free survival 2 years after DLI were 66.7% ± 3.08% and 59.8% ± 4.11%, respectively. DLI from a second donor may be an effective treatment for SGF, and the mechanism is related to MC-to-CC conversion and activation of Foxp3 and Tregs." @default.
• W4221130267 created "2022-04-03" @default.
• W4221130267 creator A5021120390 @default.
• W4221130267 creator A5071542562 @default.
• W4221130267 creator A5074934439 @default.
• W4221130267 creator A5085142676 @default.
• W4221130267 creator A5085802117 @default.
• W4221130267 date "2022-09-01" @default.
• W4221130267 modified "2023-09-26" @default.
• W4221130267 title "RETRACTED: The impact of second-donor lymphocyte infusion on secondary graft failure after allogeneic hematopoietic stem cell transplantation through activation of Foxp3 and regulatory T cells" @default.
• W4221130267 cites W1926707446 @default.
• W4221130267 cites W1967278561 @default.
• W4221130267 cites W1987332383 @default.
• W4221130267 cites W2000007143 @default.
• W4221130267 cites W2032555045 @default.
• W4221130267 cites W2044386544 @default.
• W4221130267 cites W2056710975 @default.
• W4221130267 cites W2082032753 @default.
• W4221130267 cites W2086693026 @default.
• W4221130267 cites W2087975832 @default.
• W4221130267 cites W2115512785 @default.
• W4221130267 cites W2152512565 @default.
• W4221130267 cites W2165088034 @default.
• W4221130267 cites W2293911525 @default.
• W4221130267 cites W2300169452 @default.
• W4221130267 cites W2326708519 @default.
• W4221130267 cites W2379365975 @default.
• W4221130267 cites W2607252171 @default.
• W4221130267 cites W2740495409 @default.
• W4221130267 cites W2746174184 @default.
• W4221130267 cites W2753747592 @default.
• W4221130267 cites W2789496953 @default.
• W4221130267 cites W2799781628 @default.
• W4221130267 cites W2917606322 @default.
• W4221130267 cites W2947198846 @default.
• W4221130267 cites W2966436388 @default.
• W4221130267 cites W2974306493 @default.
• W4221130267 cites W2979470489 @default.
• W4221130267 cites W3017432029 @default.
• W4221130267 cites W3049220110 @default.
• W4221130267 cites W3126303072 @default.
• W4221130267 cites W3151646093 @default.
• W4221130267 cites W3155740597 @default.
• W4221130267 cites W3200019819 @default.
• W4221130267 cites W3202594164 @default.
• W4221130267 cites W4236161341 @default.
• W4221130267 doi "https://doi.org/10.1016/j.jcyt.2022.02.008" @default.
• W4221130267 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35365413" @default.
• W4221130267 hasPublicationYear "2022" @default.
• W4221130267 type Work @default.
• W4221130267 citedByCount "1" @default.
• W4221130267 countsByYear W42211302672023 @default.
• W4221130267 crossrefType "journal-article" @default.
• W4221130267 hasAuthorship W4221130267A5021120390 @default.
• W4221130267 hasAuthorship W4221130267A5071542562 @default.
• W4221130267 hasAuthorship W4221130267A5074934439 @default.
• W4221130267 hasAuthorship W4221130267A5085142676 @default.
• W4221130267 hasAuthorship W4221130267A5085802117 @default.
• W4221130267 hasBestOaLocation W42211302671 @default.
• W4221130267 hasConcept C109159458 @default.
• W4221130267 hasConcept C126322002 @default.
• W4221130267 hasConcept C141071460 @default.
• W4221130267 hasConcept C147483822 @default.
• W4221130267 hasConcept C188280979 @default.
• W4221130267 hasConcept C203014093 @default.
• W4221130267 hasConcept C2777408962 @default.
• W4221130267 hasConcept C2779695342 @default.
• W4221130267 hasConcept C2779727006 @default.
• W4221130267 hasConcept C28328180 @default.
• W4221130267 hasConcept C2911091166 @default.
• W4221130267 hasConcept C54355233 @default.
• W4221130267 hasConcept C71924100 @default.
• W4221130267 hasConcept C86803240 @default.
• W4221130267 hasConcept C8891405 @default.
• W4221130267 hasConcept C90924648 @default.
• W4221130267 hasConceptScore W4221130267C109159458 @default.
• W4221130267 hasConceptScore W4221130267C126322002 @default.
• W4221130267 hasConceptScore W4221130267C141071460 @default.
• W4221130267 hasConceptScore W4221130267C147483822 @default.
• W4221130267 hasConceptScore W4221130267C188280979 @default.
• W4221130267 hasConceptScore W4221130267C203014093 @default.
• W4221130267 hasConceptScore W4221130267C2777408962 @default.
• W4221130267 hasConceptScore W4221130267C2779695342 @default.
• W4221130267 hasConceptScore W4221130267C2779727006 @default.
• W4221130267 hasConceptScore W4221130267C28328180 @default.
• W4221130267 hasConceptScore W4221130267C2911091166 @default.
• W4221130267 hasConceptScore W4221130267C54355233 @default.
• W4221130267 hasConceptScore W4221130267C71924100 @default.
• W4221130267 hasConceptScore W4221130267C86803240 @default.
• W4221130267 hasConceptScore W4221130267C8891405 @default.
• W4221130267 hasConceptScore W4221130267C90924648 @default.
• W4221130267 hasIssue "9" @default.
• W4221130267 hasLocation W42211302671 @default.
• W4221130267 hasLocation W42211302672 @default.
• W4221130267 hasOpenAccess W4221130267 @default.
• W4221130267 hasPrimaryLocation W42211302671 @default.
• W4221130267 hasRelatedWork W1713072761 @default.
• W4221130267 hasRelatedWork W2033219189 @default.

• next